Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer-Reference-Cited by-同舟云学术

Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer

Published:2022-03-19 Issue:9 Volume:70 Page:812-817
ISSN:1863-6705
Container-title:General Thoracic and Cardiovascular Surgery
language:en
Short-container-title:Gen Thorac Cardiovasc Surg

Author:

Ueno Tsuyoshi^ORCID,Yamashita Motohiro,Yamashita Natsumi,Uomoto Masashi,Kawamata Osamu,Sano Yoshifumi,Inokawa Hidetoshi,Hirayama Shin,Okazaki Mikio,Toyooka Shinichi

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s11748-022-01798-3.pdf

Reference13 articles.

1. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415–26.

2. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.

3. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.

4. Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Ozguroglu M, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31(6):798–806.

5. Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, et al. Comparison of survival rates after a combination of local treatment and systemic therapy vs systemic therapy alone for treatment of stage IV non-small cell lung cancer. JAMA Netw Open. 2019;2(8):e199702.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage lung resection after immunotherapy is feasible and safe;JTCVS Open;2024-08

2. Salvage extended surgery after immune-checkpoint inhibitor treatment for advanced non-small cell lung cancer;Surgery Today;2024-03-22

3. Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery;Surgery Today;2024-03-14

4. Predictors, surrogate, and patient-reported outcomes in immunotherapy and salvage surgery for unresectable lung cancer: a single-center retrospective study;Updates in Surgery;2023-09-05

5. Tumor Endothelial Cells-Associated Integrin Alpha-6 as a Promising Biomarker for Early Detection and Prognosis of Hepatocellular Carcinoma;Cancers;2023-08-17